BACKGROUND: Self-expandable metal stents (SEMSs) are the main palliative modality used in inoperable oesophageal cancer. Other palliative modalities, including argon plasma coagulation (APC), have also been used. OBJECTIVE: The purpose of this study was to assess the relative efficacy of SEMS and APC regarding the survival of patients with inoperable oesophageal cancer, not receiving chemo/radiotherapy. METHODS: Single centre, retrospective analysis of all patients (n = 228) with inoperable oesophageal cancer between January 2000 and July 2014, not receiving chemo-radiotherapy, treated with SEMS (n = 160) or APC (n = 68) as primary palliation modalities. Cox regression analysis was performed to identify individual factors affecting survival and Kaplan-Meier curves were created for patients treated with APC and SEMS for stage III and IV disease. Survival intervals were compared by the log-rank test. RESULTS: Type of treatment was the only statistically significant factor affecting survival, after disease stage stratification (hazard ratio (HR): 1.36, 95% confidence interval (CI): 1.13-1.65 of SEMS over APC, p: 0.002). Median survival for patients treated with APC and SEMS was 257 (interquartile range (IQR): 414, 124) and 151 (IQR: 241, 61) days respectively in stage III disease. It was 135 (IQR: 238, 43) and 70 (IQR: 148, 32) days respectively in stage IV disease. Both differences were statistically significant (p = 0.02 and 0.05 respectively). CONCLUSIONS: APC is a promising palliation modality in inoperable oesophageal cancer, when patients are not candidates for chemo-radiotherapy. A randomized controlled trial will be needed to confirm those results.
BACKGROUND: Self-expandable metal stents (SEMSs) are the main palliative modality used in inoperable oesophageal cancer. Other palliative modalities, including argon plasma coagulation (APC), have also been used. OBJECTIVE: The purpose of this study was to assess the relative efficacy of SEMS and APC regarding the survival of patients with inoperable oesophageal cancer, not receiving chemo/radiotherapy. METHODS: Single centre, retrospective analysis of all patients (n = 228) with inoperable oesophageal cancer between January 2000 and July 2014, not receiving chemo-radiotherapy, treated with SEMS (n = 160) or APC (n = 68) as primary palliation modalities. Cox regression analysis was performed to identify individual factors affecting survival and Kaplan-Meier curves were created for patients treated with APC and SEMS for stage III and IV disease. Survival intervals were compared by the log-rank test. RESULTS: Type of treatment was the only statistically significant factor affecting survival, after disease stage stratification (hazard ratio (HR): 1.36, 95% confidence interval (CI): 1.13-1.65 of SEMS over APC, p: 0.002). Median survival for patients treated with APC and SEMS was 257 (interquartile range (IQR): 414, 124) and 151 (IQR: 241, 61) days respectively in stage III disease. It was 135 (IQR: 238, 43) and 70 (IQR: 148, 32) days respectively in stage IV disease. Both differences were statistically significant (p = 0.02 and 0.05 respectively). CONCLUSIONS: APC is a promising palliation modality in inoperable oesophageal cancer, when patients are not candidates for chemo-radiotherapy. A randomized controlled trial will be needed to confirm those results.
Authors: Nicole C M van Heel; Jelle Haringsma; Henk Boot; Annemieke Cats; Steven A L W Vanhoutvin; Ernst J Kuipers Journal: Gastrointest Endosc Date: 2012-07 Impact factor: 9.427
Authors: Stefano Marventano; Giuseppe Grosso; Antonio Mistretta; Marta Bogusz-Czerniewicz; Roberta Ferranti; Francesca Nolfo; Gabriele Giorgianni; Stefania Rametta; Filippo Drago; Francesco Basile; Antonio Biondi Journal: Int J Colorectal Dis Date: 2014-07-27 Impact factor: 2.571
Authors: H J Wagner; K Knyrim; N Bethge; E Starck; N Sommer; J Pausch; D von Kleist Journal: Dtsch Med Wochenschr Date: 1992-02-14 Impact factor: 0.628
Authors: A Eickhoff; R Jakobs; D Schilling; D Hartmann; U Weickert; M D Enderle; J C Eickhoff; J F Riemann Journal: Endoscopy Date: 2007-07 Impact factor: 10.093
Authors: Massimo Conio; Alessandro Repici; Giorgio Battaglia; Giovanni De Pretis; Luigi Ghezzo; Max Bittinger; Helmut Messmann; Jean-François Demarquay; Sabrina Blanchi; Michele Togni; Rita Conigliaro; Rosangela Filiberti Journal: Am J Gastroenterol Date: 2007-12 Impact factor: 10.864
Authors: Simon K H Wong; Philip W Y Chiu; S F Leung; K Y Cheung; Angus C W Chan; Alex C M Au-Yeung; James F Griffith; Sydney S C Chung; Enders K W Ng Journal: Ann Surg Oncol Date: 2007-12-05 Impact factor: 5.344